Oramed Pharmaceuticals (ORMP)
(Delayed Data from NSDQ)
$2.37 USD
+0.02 (0.85%)
Updated Apr 24, 2024 03:59 PM ET
After-Market: $2.38 +0.01 (0.42%) 6:38 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Oramed Pharmaceuticals Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 1 | 3 | 1 | 3 | 3 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 1 | 3 | 1 | 3 | 3 |
Selling & Adminstrative & Depr. & Amort Expenses | 17 | 43 | 13 | 27 | 14 |
Income After Depreciation & Amortization | -16 | -41 | -12 | -24 | -12 |
Non-Operating Income | 23 | 4 | 0 | 1 | 1 |
Interest Expense | 2 | 1 | 0 | 0 | 0 |
Pretax Income | 5 | -38 | -12 | -23 | -12 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | -1 | -1 | -1 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 5 | -38 | -12 | -23 | -12 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 6 | -37 | -12 | -22 | -12 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -16 | -41 | -12 | -24 | -12 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -16 | -41 | -12 | -24 | -12 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 40.57 | 39.00 | 28.47 | 20.53 | 17.46 |
Diluted EPS Before Non-Recurring Items | -0.27 | -0.94 | -0.78 | -0.56 | 0.82 |
Diluted Net EPS (GAAP) | 0.14 | -0.94 | -0.78 | -0.78 | -0.56 |
Fiscal Year end for Oramed Pharmaceuticals Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.67 | 0.67 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.67 | 0.67 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 3.88 | 2.90 | 4.46 | 5.88 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -3.88 | -2.90 | -3.79 | -5.21 |
Non-Operating Income | NA | 18.38 | 0.44 | 2.48 | 1.60 |
Interest Expense | NA | 1.21 | 0.83 | 0.00 | 0.00 |
Pretax Income | NA | 13.30 | -3.28 | -1.31 | -3.61 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | -0.26 | -0.06 | -0.12 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 13.30 | -3.28 | -1.31 | -3.61 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 13.55 | -3.22 | -1.19 | -3.61 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 40.41 | 40.45 | 40.23 | 40.04 |
Diluted EPS Before Non-Recurring Items | NA | -0.08 | -0.08 | -0.03 | -0.08 |
Diluted Net EPS (GAAP) | NA | 0.33 | -0.08 | -0.03 | -0.08 |